Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis

Pharmacogenomics Journal

Volumn 13, Issue 3, 2013, Pages 235-241

  Wang, J ^a   Bansal, A T ^b   Martin, M ^c   Germer, S ^c   Benayed, R ^c   Essioux, L ^d   Lee, J S ^c,h   Begovich, A ^e   Hemmings, A ^c   Kenwright, A ^a   Taylor, K E ^f   Upmanyu, R ^a   Cutler, P ^d   Harari, O ^a   Marchini, J ^g   Criswell, L A ^f   Platt, Adam ^a,h  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b Acclarogen Ltd   (United Kingdom)

^c HOFFMANN LA ROCHE INC   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e Roche Diagnostics   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h NONE

Author keywords

Genetic; genome; rheumatoid arthritis; tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; ARTHRITIS, RHEUMATOID; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-6; MALE; METHOTREXATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84878218519     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.8     Document Type: Article

References (35)

1. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999; 42: 415-420.
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373: 659-672.
3. Newton JL, Harney SM, Wordsworth BP, Brown MA. A review of the MHC genetics of rheumatoid arthritis. Genes Immun 2004; 5: 151-157.
4. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-1213.
5. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508-514.
6. Verweij CL. Pharmacogenetics: anti-TNF therapy in RA-towards personalized medicine? Nat Rev Rheumatol 2011; 7: 136-138.
7. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-1523.
8. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997.
9. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-2980.
10. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
11. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-621.
12. McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE et al. Lipid and inflammation parameters: a translational, randomized placebo-controlled study to evaluate effects of Tocilizumab: the MEASURE study [abstract]. Arthritis Rheum 2010; 62(Suppl 10): 1441.
13. Lee JS, Wang J, Martin M, Germer S, Kenwright A, Benayed R et al. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Pharmacogenet Genomics 2011; 21: 365-374.
14. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006; 2: e190.
15. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
16. Cook RD, Weisberg S. Residuals and Influence in Regression: Monographs on Statistics and Applied Probability. Chapman & Hall: New York, 1982: 1-240.
17. Fox J. Applied Regression Analysis and Generalized Linear Models, 2nd edn. Sage Publications: Thousand Oaks, CA, 2008.
18. R Development Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2008.
19. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
20. Lange K, Cantor R, Horvath S, Perola M, Sabatti C, Sinsheimer J et al. Mendel version 4.0: a complete package for the exact genetic analysis of discrete traits in pedigree and population data sets. Am J Hum Genet 2001; 69: 504.
21. Wu TT, Lange K. Coordinate descent algorithms for lasso penalized regression. Ann Appl Stat 2008; 2: 224-244.
22. Tibshirani R. Regression shrinkage and selection via the lasso. J R Statist Soc Ser B 1996; 58: 267-288.
23. Wu TT, Chen YF, Hastie T, Sobel E, Lange K. Genome-wide association analysis by lasso penalized logistic regression. Bioinformatics 2009; 25: 714-721.
24. Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am J Hum Genet 2010; 86: 6-22.
25. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.
26. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39: 906-913.
27. Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinform 2010; 11: 134.
28. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011; 63: 43-52.
29. Sattler S, Ghadially H, Reiche D, Karas I, Hofer E. Evolutionary development and expression pattern of the myeloid lectin-like receptor gene family encoded within the NK gene complex. Scand J Immunol 2010; 72: 309-318.
30. Bambard ND, Mathew SO, Mathew PA. LLT1-mediated activation of IFN-gamma production in human natural killer cells involves ERK signalling pathway. Scand J Immunol 2010; 71: 210-219.
31. Hu YS, Zhou H, Myers D, Quinn JM, Atkins GJ, Ly C et al. Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. J Bone Miner Res 2004; 19: 89-99.
32. Zhou H, Kartsogiannis V, Hu YS, Elliott J, Quinn JM, McKinstry WJ et al. A novel osteoblast-derived C-type lectin that inhibits osteoclast formation. J Biol Chem 2001; 276: 14916-14923.
33. Maggi L, Santarlasci V, Capone M, Peired A, Frosali F, Crome SQ et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 2010; 40: 2174-2181.
34. Marzio R, Mauel J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol 1999; 21: 565-582.
35. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.